Market Overview:
Gene Therapy Market size was valued at USD 6.39 Billion in 2021 and is poised to grow from USD 7.60 Billion in 2022 to USD 38.34 Billion by 2030, at a CAGR of 19% during the forecast period (2023-2030). The global gene therapy market is a rapidly growing market that is poised for significant growth in the coming years. The purpose of the gene therapy market is to provide a cure for genetic disorders that are currently untreatable. Gene therapy market is focused on developing new and innovative therapies that can address the root cause of these diseases.
The key driving factors for the gene therapy market is the increasing prevalence of genetic disorders. The prevalence of genetic disorders is increasing globally, which is driving the demand for gene therapy. The main restraints for the gene therapy market are the high cost of these therapies. Gene therapies are complex and expensive to develop, which results in high costs for patients. The delivery mechanism is critical for the success of gene therapies, as it needs to deliver the healthy gene to the targeted cells in the body.
Market Insights:
Gene Therapy Market Drivers
Increasing Prevalence of Genetic Disorders
- Genetic disorders, such as spinal muscular atrophy, cystic fibrosis, and hemophilia, are on the rise worldwide. The increasing prevalence of these disorders is driving the growth of the gene therapy market, as gene therapies have shown promising results in the treatment of these disorders.
Rising Demand for Personalized Medicine
- Gene therapy offers personalized treatment options that can be tailored to individual patients based on their genetic makeup. As the demand for personalized medicine continues to rise, the gene therapy market is expected to grow significantly.
Download a detailed overview:
https://www.skyquestt.com/sample-request/gene-therapy-market
Key Market Segments:
Vector
Lentivirus, AAV, Retrovirus & gamma Retrovirus, Modified Herpes Simplex Virus, Adenovirus, Non-viral Plasmid Vector, and Others
Indication
Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease, Large B-cell Lymphoma, Melanoma (lesions), Beta-Thalassemia Major/SCD, Head & Neck Squamous Cell Carcinoma, Peripheral arterial disease, Spinal Muscular Atrophy (SMA), and Others
Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/healthcare-analytics-market
Gene Therapy Market Analysis by Vector
In 2022, retroviruses segment accounted for over 20% of the revenue share in the global gene therapy market due to their ease of isolation and incorporation of DNA into the virus, allowing the conversion of single-stranded RNA to double-stranded DNA for integration into host cell chromosomes. Ongoing clinical trials are predominantly using retroviruses, and the approval of Yes carta in 2017 has led to a significant revenue growth in this segment.
Meanwhile, Adeno-Associated Viral (AAV) vectors are expected to show substantial market share growth in the future. AAVs have become highly sought after and their clinical trial applications are increasing annually due to their ability to deliver genes to the region of interest with the highest efficiency. The rise of AAV usage can be attributed to the success of orthopedic and ocular gene therapy treatments, which have shown increased efficacy. Therefore, AAV is expected to witness a significant adoption rate boost in various therapeutic fields during the forecast period.
Regional Insights:
In 2022, North America emerged as the dominant region in the gene therapy market, contributing to over 65.0% of the overall revenue. It is projected to remain the largest routine manufacturer of gene therapy drugs during the forecast period, with increasing investments in R&D by companies of all sizes. The market is being driven by rising government investments and the growing prevalence of targeted diseases in the region, such as spinal muscular atrophy, affecting 10,000 to 25,000 individuals in the U.S. alone, according to the Spinal Muscular Atrophy Foundation.
Asia Pacific is expected to be the fastest-growing regional segment from 2023 to 2030, owing to its large population with unmet medical needs and the growing demand for innovative technologies to treat rare but increasingly prevalent diseases. The commercial application of genetic therapies is likely to witness significant growth in this region due to the availability of resources, the presence of major companies, and government investments.
Prominent Players in Gene Therapy Market:
- Novartis International AG (Switzerland)
- Pfizer Inc. (US)
- Biogen Inc. (US)
- Spark Therapeutics Inc. (US)
- Sarepta Therapeutics Inc. (US)
- bluebird bio-Inc. (US)
- Gilead Sciences Inc. (US)
- Amgen Inc. (US)
- Regenxbio Inc. (US)
- Krystal Biotech Inc. (US)
- uniQure N.V. (Netherlands)
- Avexis Inc. (US)
- Orchard Therapeutics plc (UK)
- Abeona Therapeutics Inc. (US)
- Solid Biosciences Inc. (US)
- Audentes Therapeutics Inc. (US)
- Adaptimmune Therapeutics plc (UK)
- Intellia Therapeutics Inc. (US)
- Editas Medicine Inc. (US)
- Precision BioSciences Inc. (US)
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/gene-therapy-market
Additional Insights:
Market Penetration: Analysis of the product portfolio of different market players and the status of new product launches.
Product Development/Innovation: Assessment of R&D activities, new product development, and emerging trends.
Market Development: Analysis of regions with high growth potential.
Market Diversification: Assessment of new products, recent developments, and emerging regional markets.
Competitive Landscape: Growth strategies, revenue analysis, and product innovations by market players.
Key Questions Answered in Gene Therapy Market Report:
What is the global market size of the Gene Therapy Market?
Who are the key vendors in the Gene Therapy Market?
What is the key driver of the Gene Therapy Market?
What is the key market trend for the Gene Therapy Market?
Which region accounted for the largest share in the Gene Therapy Market?
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:
Mr. Jagraj Singh
Skyquest Technology
1 Apache Way,
Westford,
Massachusetts 01886
USA (+1) 351-333-4748
Email: [email protected]
Visit Our Website: https://www.skyquestt.com/
